Karyopharm submits nda to u.s. fda for xpovio as a treatment for patients with relapsed or refractory diffuse large b-cell lymphoma

Karyopharm submits new drug application to u.s. fda for xpovio® (selinexor) as a treatment for patients with relapsed or refractory diffuse large b-cell lymphoma.karyopharm therapeutics inc - expects to submit a marketing authorization application (maa) to european medicines agency in 2020 for xpovio.
KPTI Ratings Summary
KPTI Quant Ranking